The Aroon Indicator for AORT entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 137 similar instances where the Aroon Indicator formed such a pattern. In 101 of the 137 cases the stock moved lower. This puts the odds of a downward move at 74%.
The 10-day moving average for AORT crossed bearishly below the 50-day moving average on September 10, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 54%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AORT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AORT's RSI Indicator exited the oversold zone, 17 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 53 cases where AORT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for AORT just turned positive on October 14, 2026. Looking at past instances where AORT's MACD turned positive, the stock continued to rise in 36 of 48 cases over the following month. The odds of a continued upward trend are 75%.
Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where AORT advanced for three days, in 222 of 302 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 81 (best 1 - 100 worst), indicating slightly worse than average price growth. AORT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.511) is normal, around the industry mean (10.930). P/E Ratio (104.680) is within average values for comparable stocks, (100.178). Projected Growth (PEG Ratio) (4.200) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (2.603) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AORT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The RSI Indicator for FOCL moved out of oversold territory on September 17, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 37 similar instances when the indicator left oversold territory. In 30 of the 37 cases the stock moved higher. This puts the odds of a move higher at 81%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where FOCL advanced for three days, in 184 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FOCL as a result. In 68 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 77%.
The Moving Average Convergence Divergence Histogram (MACD) for FOCL turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 37 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOCL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
FOCL broke above its upper Bollinger Band on September 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for FOCL entered a downward trend on September 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. FOCL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (22.472) is normal, around the industry mean (2.488). FOCL has a moderately high P/E Ratio (100.000) as compared to the industry average of (39.020). FOCL's Projected Growth (PEG Ratio) (8.100) is very high in comparison to the industry average of (2.016). Dividend Yield (0.000) settles around the average of (0.004) among similar stocks. P/S Ratio (1.919) is also within normal values, averaging (4.260).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOCL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 74, placing this stock worse than average.
AORT | FOCL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 68 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 100 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 91 | 100 | |
PRICE GROWTH RATING 1..100 | 81 | 41 | |
P/E GROWTH RATING 1..100 | 88 | 99 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AORT's Valuation (92) in the Medical Specialties industry is in the same range as FOCL (100) in the Biotechnology industry. This means that AORT’s stock grew similarly to FOCL’s over the last 12 months.
AORT's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as FOCL (100) in the Biotechnology industry. This means that AORT’s stock grew similarly to FOCL’s over the last 12 months.
AORT's SMR Rating (91) in the Medical Specialties industry is in the same range as FOCL (100) in the Biotechnology industry. This means that AORT’s stock grew similarly to FOCL’s over the last 12 months.
FOCL's Price Growth Rating (41) in the Biotechnology industry is somewhat better than the same rating for AORT (81) in the Medical Specialties industry. This means that FOCL’s stock grew somewhat faster than AORT’s over the last 12 months.
AORT's P/E Growth Rating (88) in the Medical Specialties industry is in the same range as FOCL (99) in the Biotechnology industry. This means that AORT’s stock grew similarly to FOCL’s over the last 12 months.
| AORT | FOCL | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | 1 day ago 81% |
| Stochastic ODDS (%) | 1 day ago 79% | 1 day ago 76% |
| Momentum ODDS (%) | N/A | 1 day ago 77% |
| MACD ODDS (%) | 1 day ago 75% | 1 day ago 88% |
| TrendWeek ODDS (%) | 1 day ago 68% | 1 day ago 84% |
| TrendMonth ODDS (%) | 1 day ago 68% | 1 day ago 85% |
| Advances ODDS (%) | 3 days ago 74% | 3 days ago 76% |
| Declines ODDS (%) | 7 days ago 67% | 1 day ago 84% |
| BollingerBands ODDS (%) | N/A | 1 day ago 78% |
| Aroon ODDS (%) | 1 day ago 74% | 1 day ago 89% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AORT’s FA Score shows that 0 FA rating(s) are green while FOCL’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AORT’s TA Score shows that 4 TA indicator(s) are bullish while FOCL’s TA Score has 3 bullish TA indicator(s).
AORT (@Medical/Nursing Services) experienced а -0.37% price change this week, while FOCL (@Medical Distributors) price change was -4.77% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -4.79%. For the same industry, the average monthly price growth was -7.51%, and the average quarterly price growth was -14.87%.
The average weekly price growth across all stocks in the @Medical Distributors industry was +2.01%. For the same industry, the average monthly price growth was +23.42%, and the average quarterly price growth was -24.55%.
AORT is expected to report earnings on Oct 29, 2026.
The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Distributors (+2.01% weekly)Healthcare distribution market can be segmented into pharmaceutical product distribution services, medical device distribution services, and biopharmaceutical product distribution services. In addition to serving as intermediaries, many medical distributors also purchase and take legal ownership of pharmaceuticals and manage inventory and credit risk. According to a Deloitte report, pharmaceutical distributors’ core services of efficient product distribution, inventory management, financial risk management, and information-sharing generate $33 billion-$53 billion in value annually to the U.S. health care ecosystem. Some prominent players in the overall medical distribution industry include McKesson Corporation, AmerisourceBergen Corporation, Cardinal Health, Inc. and Patterson Companies, Inc.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TBJL | 18.62 | 0.09 | +0.46% |
| Innovator 20+ Year Treasury Bond 9 Buffer ETF - July (TBJL) | |||
| TXUE | 34.59 | -0.11 | -0.32% |
| Thornburg International Equity ETF (TXUE) | |||
| TOLZ | 56.52 | -0.27 | -0.48% |
| ProShares DJ Brookfield Global Infrastructure ETF (TOLZ) | |||
| ATCL | 24.48 | -0.15 | -0.60% |
| Rex Autocallable Income ETF | |||
| JIVE | 94.03 | -0.79 | -0.83% |
| JPMorgan International Value ETF (JIVE) | |||
A.I.dvisor indicates that over the last year, AORT has been loosely correlated with VREX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AORT jumps, then VREX could also see price increases.
| Ticker / NAME | Correlation To AORT | 1D Price Change % | ||
|---|---|---|---|---|
| AORT | 100% | +0.80% | ||
| VREX - AORT | 55% Loosely correlated | -0.43% | ||
| TCMD - AORT | 43% Loosely correlated | +0.45% | ||
| LMAT - AORT | 42% Loosely correlated | +1.31% | ||
| ISRG - AORT | 39% Loosely correlated | -0.43% | ||
| UTMD - AORT | 39% Loosely correlated | +0.11% | ||
More | ||||
A.I.dvisor tells us that FOCL and AORT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that FOCL and AORT's prices will move in lockstep.
| Ticker / NAME | Correlation To FOCL | 1D Price Change % | ||
|---|---|---|---|---|
| FOCL | 100% | -5.00% | ||
| AORT - FOCL | 29% Poorly correlated | +0.80% | ||
| UFPT - FOCL | 20% Poorly correlated | -1.08% | ||
| SENS - FOCL | 20% Poorly correlated | -9.19% | ||
| STXS - FOCL | 16% Poorly correlated | -0.94% | ||
| HBIO - FOCL | 11% Poorly correlated | -1.45% | ||
More | ||||